Abbisko Celebrates Achievement at ESMO 2024
Abbisko Therapeutics is thrilled to announce that they have received the Best Poster Award at ESMO 2024. Their presentation highlighted crucial findings related to the safety and effectiveness of Irpagratinib (ABSK011) for treating advanced hepatocellular carcinoma (aHCC), especially in patients with FGF19 overexpression. This award reflects Abbisko's commitment and notable progress in addressing significant unmet needs in cancer treatment.
Key Findings on Irpagratinib
Impressive Results from the Study
A key highlight from the ABSK-011-101 study is the encouraging data for Irpagratinib monotherapy. The study shows a well-tolerated safety profile and significant anti-tumor activity. Specifically, in patients who previously underwent treatment with both immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs), the Objective Response Rate (ORR) was an impressive 44.8%, meaning nearly half of the patients experienced a substantial reduction in tumors. Furthermore, the Disease Control Rate (DCR) reached 79.3%, showcasing the drug’s ability to provide meaningful clinical benefits to those with pressing medical needs.
Patient Insights
According to the latest data, a total of 122 patients participated in this clinical trial, with many categorized under BCLC Stage C, an advanced stage of liver cancer. The treatment responses revealed that, among specific subsets treated with a 220mg BID dose, there was a response rate of around 36.8% among evaluable patients. Additionally, the median duration of response (mDoR) was 7.4 months, and the median progression-free survival (mPFS) was recorded at 5.5 months, further supporting the case for further development of Irpagratinib for patients in this treatment scenario.
Safety Profile and Tolerability of Irpagratinib
While assessing the efficacy of Irpagratinib is vital, it's also essential to understand its safety profile. In the 300mg BID treatment group, only one instance of dose-limiting toxicity was reported, and the most common treatment-related adverse effects included increases in liver enzymes and gastrointestinal issues. Notably, there were no reports of grade 5 adverse events, underscoring the drug’s favorable safety profile, which supports its potential as a viable treatment option for patients afflicted by advanced liver cancer.
Importance of HCC Research
Hepatocellular carcinoma is a serious malignancy, representing 85% to 90% of primary liver cancers, recognized for its aggressive nature and poor prognosis. Current therapies have not sufficiently improved survival rates for many patients. The innovative strategy of targeting the FGF19/FGFR4 signaling pathway is being further explored with Irpagratinib. As a selective FGFR4 inhibitor, it aims to address specific molecular abnormalities in tumors, promising tailored treatments for patients battling this type of cancer.
About Irpagratinib and Abbisko Therapeutics
Irpagratinib represents a significant advancement in the treatment options available for advanced solid tumors, particularly in hepatocellular carcinoma and other cancers where abnormalities in the FGF19/FGFR4 pathway are present. Abbisko Therapeutics, founded in 2016, remains dedicated to discovering and developing innovative cancer therapies for patients in China and beyond. With a robust pipeline of drug candidates, Abbisko is focused on precision oncology, poised to make substantial impacts in the medical field and the lives of patients.
Frequently Asked Questions
What does the ESMO 2024 Best Poster Award signify?
The award emphasizes the clinical significance and innovation showcased in the research, setting it apart in the scientific community.
Who stands to gain from Irpagratinib treatment?
Patients with advanced hepatocellular carcinoma, especially those demonstrating strong FGF19 overexpression and who have received multiple prior treatments, are the main beneficiaries of this therapy.
What side effects are commonly associated with Irpagratinib?
Common side effects include elevated liver enzymes, diarrhea, and gastrointestinal discomfort, although the overall safety profile remains favorable.
Is Irpagratinib included in a broader clinical development plan?
Yes, Abbisko Therapeutics is actively pursuing late-stage development of Irpagratinib, aiming to broaden its application for various patient populations.
How does Abbisko Therapeutics impact the field of oncology?
Abbisko focuses on discovering and developing targeted therapies to address unmet medical needs, thereby improving treatment outcomes for cancer patients globally.
